Research Analysts Issue Forecasts for CADL FY2027 Earnings

Candel Therapeutics, Inc. (NASDAQ:CADL – Free Report) – Stock analysts at Brookline Capital Markets issued their FY2027 EPS estimates for Candel Therapeutics in a research report issued on Friday, November 13th. Brookline Capital Markets analyst K. Dolliver expects that the company will earn ($1.52) per share for the year. The consensus estimate for Candel Therapeutics’ current full-year earnings is ($1.29) per share.

CADL has been the subject of a number of other research reports. Stifel Nicolaus decreased their target price on shares of Candel Therapeutics from $22.00 to $19.00 and set a “buy” rating for the company in a research report on Friday. UBS Group reaffirmed a “buy” rating on shares of Candel Therapeutics in a report on Monday, August 17th. Zacks Research lowered shares of Candel Therapeutics from a “hold” rating to a “strong sell” rating in a report on Wednesday, October 14th. Citigroup decreased their price objective on Candel Therapeutics from $26.00 to $20.00 and set a “buy” rating for the company in a report on Monday. Finally, Wall Street Zen cut Candel Therapeutics from a “hold” rating to a “sell” rating in a research report on Sunday, August 16th. Nine research analysts have rated the stock with a Buy rating and two have given a Sell rating to the stock. According to data from MarketBeat, Candel Therapeutics has an average rating of “Moderate Buy” and an average price target of $18.29.

View Our Latest Analysis on CADL

Candel Therapeutics Trading Down 6.3%

NASDAQ CADL opened at $5.81 on Monday. The company has a quick ratio of 16.09, a current ratio of 16.09 and a debt-to-equity ratio of 0.38. The firm has a market cap of $444.58 million, a PE ratio of -3.93 and a beta of -0.27. The company has a 50 day moving average price of $9.61 and a 200 day moving average price of $8.39. Candel Therapeutics has a 52 week low of $4.35 and a 52 week high of $14.00.

Candel Therapeutics (NASDAQ:CADL – Get Free Report) last issued its quarterly earnings data on Friday, November 13th. The company reported ($0.28) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.34) by $0.06.

Hedge Funds Weigh In On Candel Therapeutics

Several hedge funds have recently modified their holdings of the stock. Goldman Sachs Group Inc. grew its position in Candel Therapeutics by 4.1% during the 3rd quarter. Goldman Sachs Group Inc. now owns 317,601 shares of the company’s stock worth $3,316,000 after purchasing an additional 12,385 shares during the last quarter. Cetera Investment Advisers acquired a new position in Candel Therapeutics during the 3rd quarter valued at approximately $124,000. Entropy Technologies LP acquired a new position in Candel Therapeutics during the 3rd quarter valued at approximately $266,000. Jump Financial LLC increased its stake in Candel Therapeutics by 22.2% during the 3rd quarter. Jump Financial LLC now owns 130,579 shares of the company’s stock valued at $1,363,000 after purchasing an additional 23,739 shares in the last quarter. Finally, ACT Capital Partners L.P. purchased a new position in shares of Candel Therapeutics in the third quarter worth $1,571,000. Institutional investors and hedge funds own 13.93% of the company’s stock.

Latest Candel Therapeutics News

These are some of the CADL news items that stood out recently:

  • Neutral Sentiment: Citigroup kept a Buy rating but cut its price target from $26 to $20. HC Wainwright also has a Buy rating and an $18 target, though its target was reduced. The retained Buy ratings offer support, but the lower targets reflect reassessment after the delay. Citigroup price-target update HC Wainwright price-target update
  • Negative Sentiment: Candel pushed its planned biologics license application (BLA) submission for aglatimagene, its most advanced candidate for prostate cancer, to mid-2027. The delay followed prior expectations for an earlier filing and contributed to a sharp selloff, raising concerns about execution and the timing of a key potential catalyst. Candel delays prostate cancer filing to mid-2027
  • Negative Sentiment: Two law firms announced investigations into whether Candel’s statements about the BLA timeline violated securities laws. These are allegations under investigation, not findings of wrongdoing, but add legal and reputational uncertainty for investors. Levi & Korsinsky investigation notice Hagens Berman investigation announcement

Candel Therapeutics Company Profile

(Get Free Report)

Candel Therapeutics is a clinical-stage biotechnology company developing viral immunotherapies designed to stimulate the immune system to fight cancer. Its approach uses engineered viruses to trigger immune responses against tumors. The company’s clinical-stage programs include CAN-2409, an adenovirus-based therapy being studied in several solid tumors, and CAN-3110, an oncolytic herpes simplex virus therapy being investigated for recurrent glioblastoma. Based in Needham, Massachusetts, Candel conducts clinical development of its therapies for cancer indications.

Featured Articles

Earnings History and Estimates for Candel Therapeutics (NASDAQ:CADL)

Receive News & Ratings for Candel Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Candel Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.